GB201614744D0 - Modulation of gene expression and screening for deregulated protein expression - Google Patents

Modulation of gene expression and screening for deregulated protein expression

Info

Publication number
GB201614744D0
GB201614744D0 GBGB1614744.9A GB201614744A GB201614744D0 GB 201614744 D0 GB201614744 D0 GB 201614744D0 GB 201614744 A GB201614744 A GB 201614744A GB 201614744 D0 GB201614744 D0 GB 201614744D0
Authority
GB
United Kingdom
Prior art keywords
screening
modulation
expression
gene expression
deregulated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1614744.9A
Other versions
GB2559100A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to GB1614744.9A priority Critical patent/GB2559100A/en
Priority to AU2016334804A priority patent/AU2016334804B2/en
Priority to PCT/GB2016/053136 priority patent/WO2017060731A1/en
Priority to KR1020227024328A priority patent/KR20220105174A/en
Priority to KR1020187012992A priority patent/KR102422625B1/en
Priority to CN201680072628.XA priority patent/CN108603230A/en
Priority to CA3000971A priority patent/CA3000971A1/en
Priority to IL308174A priority patent/IL308174A/en
Priority to US15/288,415 priority patent/US10196639B2/en
Priority to EP16781187.6A priority patent/EP3359685A1/en
Priority to JP2018518426A priority patent/JP6923517B2/en
Priority to SG11201802870RA priority patent/SG11201802870RA/en
Publication of GB201614744D0 publication Critical patent/GB201614744D0/en
Priority to IL258528A priority patent/IL258528A/en
Publication of GB2559100A publication Critical patent/GB2559100A/en
Priority to US16/213,535 priority patent/US10941405B2/en
Priority to US17/159,881 priority patent/US11702660B2/en
Priority to JP2021123345A priority patent/JP2021180669A/en
Priority to AU2022204606A priority patent/AU2022204606A1/en
Priority to US18/299,509 priority patent/US20230416756A1/en
Priority to JP2023171631A priority patent/JP2024009853A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1614744.9A 2015-10-09 2016-08-31 Modulation of gene expression and screening for deregulated protein expression Withdrawn GB2559100A (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GB1614744.9A GB2559100A (en) 2016-08-31 2016-08-31 Modulation of gene expression and screening for deregulated protein expression
US15/288,415 US10196639B2 (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
SG11201802870RA SG11201802870RA (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
PCT/GB2016/053136 WO2017060731A1 (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
KR1020227024328A KR20220105174A (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
KR1020187012992A KR102422625B1 (en) 2015-10-09 2016-10-07 Regulation of gene expression and screening of deregulated protein expression
CN201680072628.XA CN108603230A (en) 2015-10-09 2016-10-07 The screening of the adjusting of gene expression and protein expression imbalance
CA3000971A CA3000971A1 (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
IL308174A IL308174A (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
AU2016334804A AU2016334804B2 (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
EP16781187.6A EP3359685A1 (en) 2015-10-09 2016-10-07 Modulation of gene expression and screening for deregulated protein expression
JP2018518426A JP6923517B2 (en) 2015-10-09 2016-10-07 Screening for regulatory and deregulated protein expression of gene expression
IL258528A IL258528A (en) 2015-10-09 2018-04-08 Modulation of gene expression and screening for deregulated protein expression
US16/213,535 US10941405B2 (en) 2015-10-09 2018-12-07 Modulation of gene expression and screening for deregulated protein expression
US17/159,881 US11702660B2 (en) 2015-10-09 2021-01-27 Modulation of gene expression and screening for deregulated protein expression
JP2021123345A JP2021180669A (en) 2015-10-09 2021-07-28 Adjustment of gene expression and screening of expression of dyscontrol protein
AU2022204606A AU2022204606A1 (en) 2015-10-09 2022-06-29 Modulation of gene expression and screening for deregulated protein expression
US18/299,509 US20230416756A1 (en) 2015-10-09 2023-04-12 Modulation of gene expression and screening for deregulated protein expression
JP2023171631A JP2024009853A (en) 2015-10-09 2023-10-02 Modulation of gene expression and screening for deregulated protein expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1614744.9A GB2559100A (en) 2016-08-31 2016-08-31 Modulation of gene expression and screening for deregulated protein expression

Publications (2)

Publication Number Publication Date
GB201614744D0 true GB201614744D0 (en) 2016-10-12
GB2559100A GB2559100A (en) 2018-08-01

Family

ID=57119977

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1614744.9A Withdrawn GB2559100A (en) 2015-10-09 2016-08-31 Modulation of gene expression and screening for deregulated protein expression

Country Status (1)

Country Link
GB (1) GB2559100A (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2591194B (en) * 2015-10-09 2021-10-13 Univ Southampton Modulation of gene expression and screening for deregulated protein expression

Also Published As

Publication number Publication date
GB2559100A (en) 2018-08-01

Similar Documents

Publication Publication Date Title
IL258528A (en) Modulation of gene expression and screening for deregulated protein expression
HK1252955A1 (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
SG10202112024PA (en) Chimeric proteins and methods of immunotherapy
EP3402885A4 (en) Chimeric proteins and methods of regulating gene expression
GB2546719B (en) Modulation of gene expression and screening for deregulated protein expression
EP3218483A4 (en) Compounds and methods for the modulation of proteins
HK1251969A1 (en) Anti-her2 antibodies and methods of use
HK1254289A1 (en) Methods and antibodies for modulation of immunoresponse
IL252837B (en) Fcrn antibodies and methods of use thereof
EP3240799A4 (en) S-alkylated hepcidin peptides and methods of making and using thereof
IL264528B1 (en) Fcrn antibodies and methods of use thereof
SI3227311T1 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
EP3268477A4 (en) Structure based methods for modification of pip-72 polypeptides and pip-72 polypeptides derived therefrom
HK1255456A1 (en) Expression of fc-containing proteins
EP3227681A4 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
EP3535403A4 (en) Modulation of protein accumulation and uses therefor
GB201705121D0 (en) Modulation of gene expression
GB201614744D0 (en) Modulation of gene expression and screening for deregulated protein expression
AU2016904541A0 (en) Modulation of protein accumulation and uses therefor
GB201708679D0 (en) Protein expression assays and methods
AU2017901026A0 (en) Modulation of protein accumulation and uses therefor

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)